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The cholesterol transporter ABCG1 links cholesterol
homeostasis and tumour immunity
Duygu Sag1,*, Caglar Cekic2,*, Runpei Wu1, Joel Linden3 & Catherine C. Hedrick1
ATP-binding cassette transporter G1 (ABCG1) promotes cholesterol efﬂux from cells and
regulates intracellular cholesterol homeostasis. Here we demonstrate a role of ABCG1 as a
mediator of tumour immunity. Abcg1 / mice have dramatically suppressed subcutaneous
MB49-bladder carcinoma and B16-melanoma growth and prolonged survival. We show that
reduced tumour growth in Abcg1 / mice is myeloid cell intrinsic and is associated with a
phenotypic shift of the macrophages from a tumour-promoting M2 to a tumour-ﬁghting M1
within the tumour. Abcg1 / macrophages exhibit an intrinsic bias towards M1 polarization
with increased NF-kB activation and direct cytotoxicity for tumour cells in vitro. Overall, our
study demonstrates that the absence of ABCG1 inhibits tumour growth through modulation
of macrophage function within the tumour, and illustrates a link between cholesterol
homeostasis and cancer.
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I
n addition to the cancer cells and their surrounding stroma,
the tumour microenvironment contains innate and adaptive
immune cells that can recognize and destroy tumours1.
However, the tumour not only manages to evade the immune
system through various mechanisms, but also it contrives to
beneﬁt from inﬁltrating immune cells by modifying their
functions to create a microenvironment favourable to tumour
progression2. Macrophages are major players of tumour
immunity. Monocyte-derived macrophages can polarize into
either M1 (classically activated) or M2 (alternatively activated)
macrophage subtypes in the presence of speciﬁc polarization
factors, including cytokines, growth factors and bioactive lipids,
when recruited into peripheral tissues3,4. In general, M1
macrophages are potent tumour-ﬁghting cells, whereas M2
macrophages display protumoral functions. The tumour recruits
blood monocytes and promotes their differentiation mostly into
M2-like macrophages5. M2-like tumour-associated macrophages
(TAMs) play a key role in tumour growth and progression by
producing molecules to promote angiogenesis, as well as survival
and metastasis of tumour cells6–9. Moreover, TAMs affect
adaptive immune responses by recruiting T regulatory cells
(Tregs), which in turn suppress antitumour effector cells such as
NK cells and CD4þ /CD8þ T cells10. Several studies have
reported a positive correlation between high TAM density and
poor prognosis in human tumours, including bladder, breast and
prostate7,11. Furthermore, it has been shown in different murine
tumour models that either depletion of macrophages12–16 or
switching the phenotype of macrophages into tumour-ﬁghting
M1 macrophages17–19 results in a signiﬁcant reduction in tumour
growth.
ATP-binding cassette transporter G1 (ABCG1) is a member of
the ABC transporter family that regulates cellular cholesterol
homeostasis20. Cholesterol homeostasis is crucial for the survival
and function of cells21. ABCG1 efﬂuxes excess cholesterol from
cells to high-density lipoprotein (HDL) particles for reverse
cholesterol transport, which is the only path for elimination of
cholesterol from the body22,23. ABCG1 is also important for the
intracellular transport of cholesterol24,25. It is ubiquitously
expressed in many cell types including myeloid cells,
lymphocytes and endothelial cells20.
ABCG1 is known to regulate several aspects of macrophage
biology. Abcg1 / mice fed a Western-like diet display excessive
lipid accumulation in macrophages22. Atherosclerosis studies
demonstrated that ABCG1-deﬁcient macrophages were more
susceptible to apoptosis compared with wild-type (WT)
macrophages under Western-like diet conditions in vivo26,27.
Furthermore, Abcg1 / macrophages have been shown to
display enhanced proinﬂammatory cytokine production at basal
level28,29, in response to lipopolysaccharide (LPS)30 and when
loaded with cholesterol31. ABCG1 also plays a role in T-cell
biology. We and others have reported that alterations in
intracellular cholesterol homeostasis in the absence of ABCG1
increase proliferation of CD4þ T cells32,33 and impairs
development of invariant natural killer T cells in thymus34.
Overall, changes in cholesterol homeostasis by the absence of
ABCG1 modulate immune cell function; however, the role of
ABCG1 in antitumour immune responses is unknown.
In this study, we demonstrate that the in vivo deﬁciency
of ABCG1 reduces tumour growth and increases the survival of
mice. Reduced tumour growth in the absence of ABCG1 is
mediated by myeloid cell intrinsic mechanisms and is associated
with a shift of macrophages to a tumour-ﬁghting M1 phenotype
within the tumour, which results in the direct killing of
tumour cells.
Results
ABCG1 deﬁciency prevents tumour growth in mice.
To determine if ABCG1 has an impact on tumour growth,
MB49-bladder carcinoma or B16-F1 melanoma cells were
ﬁrst injected subcutaneously into 7–10-week-old Abcg1 / or
control C57BL/6 (WT) mice fed a regular rodent chow diet
(containing 0% cholesterol and 5% calories from fat; Fig. 1a).
Both groups of mice had comparable MB49 and B16-F1 tumour
sizes when fed a chow diet (Fig. 1b,c). Because ABCG1 regulates
cholesterol homeostasis in the cell, to make the impact of ABCG1
deﬁciency more prominent, 7–10-week-old Abcg1 / and WT
mice were next fed a Western-like diet (containing 0.2% choles-
terol and 42% calories from fat) beginning a week before MB49 or
B16-F1 tumour inoculation. The Western-like diet used in our
studies is very similar in cholesterol and fat content to the typical
Western-like diet chosen by many people in developed countries,
and now increasingly in developing countries. Abcg1 / mice
fed a Western-like diet displayed dramatically reduced MB49
(fourfold at day 20) and B16-F1 (approximately threefold at
day 20) tumour growth compared with control mice (Fig. 1d,e).
By 6–8 months of age, Abcg1 / mice develop age-dependent
phenotypes, such as pulmonary lipidosis and massive lipid
deposition in macrophages35 and these phenotypes are known to
be accelerated by a Western-like diet22. Therefore, we also
assessed the tumour growth in older (6–7 months old) Abcg1 /
and WT mice fed a chow diet. Interestingly, we found that aged
Abcg1 / mice when fed a chow diet had dramatically reduced
MB49 tumour growth compared with aged-matched WT controls
(Fig. 1f).
To investigate how Western-like diet affects the cholesterol
proﬁles of tumour-bearing Abcg1 / and WT mice, we
performed fast protein liquid chromatography analysis of plasma
lipoprotein cholesterol proﬁles of MB49 tumour-bearing (day 12)
7–10-week-old Abcg1 / and WT mice fed either chow or
Western-like diets. In line with the published literature on
Abcg1 / mice24,36, plasma lipoprotein cholesterol proﬁles of
tumour-bearing Abcg1 / and WT mice were similar. In
addition, Western-like diet feeding increased plasma lipoprotein
cholesterol levels in both groups of mice (Fig. 1g). To further
investigate the impact of ABCG1 deﬁciency on tumour
progression, we crossed Abcg1 / mice with apoE-deﬁcient
(ApoE / )37,38 and LDL-receptor-deﬁcient mice (Ldlr / )39,40.
Figure 1 | ABCG1 deﬁciency reduces MB49 and B16 tumour growth. (a) Schematic diagram of the experimental design is shown. Graphs show (b) MB49
and (c) B16-F1 tumour growth in chow diet-fed and (d) MB49 and (e) B16-F1 tumour growth in Western-like diet-fed 7–10-week-old Abcg1 / (n¼ 8) and
C57BL/6 (WT) mice (n¼8) and (f) MB49 tumour growth in chow diet-fed 6–7-month-old Abcg1 / (n¼6) and WT (n¼ 7) mice. (g) Blood plasma
from ﬁve tumour-bearing mice for each group was pooled and the lipoprotein proﬁle was analysed by fast protein liquid chromatography. Graph shows
VLDL, IDL/LDL and HDL levels in all groups. (h–j) Graphs show MB49 tumour growth in (h) chow diet-fed and (i) Western-like diet-fed Abcg1 /
Ldlr/ (n¼6), Ldlr/ (n¼ 5); Abcg1 /ApoE / (n¼ 8) and ApoE / (n¼ 8) mice. (j) Picture shows harvested tumour masses from
Western-like diet-fed Abcg1 /ApoE / and ApoE / mice at day 21. Data are representative of two to four independent experiments with similar
results. (mean±s.e.m., ***Po0.001, two-way analysis of variance test). (k) Graph shows Kaplan–Meier survival curve of Western-like diet-fed tumour
(MB49)-bearing Abcg1 / (n¼ 5) and WTmice (n¼ 5). Data are representative of two independent experiments with similar results (mean±s.e.m.,
*Po0.05, log-rank test). IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
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The ApoE / and Ldlr / models are two hypercholesterolemic
mouse models that are widely used to study atherosclerosis. Both
genotypes have high plasma cholesterol levels when fed a chow
diet and show profoundly increased plasma cholesterol levels when
fed a Western-like diet37–41. We ﬁrst compared the plasma
lipoprotein cholesterol proﬁles of MB49 tumour-bearing (day 12)
7–10-week-old Abcg1 / ApoE / mice with ApoE / mice
and Abcg1 / Ldlr / mice with Ldlr / mice, all fed a chow
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diet. We found that the loss of ABCG1 had no impact on plasma
lipoprotein proﬁles in tumour-bearing hypercholesterolemic
mice (Supplementary Fig. 1). We next measured subcutaneous
tumour growth in Abcg1 / mice crossed with these hyper-
cholesterolemic mouse models. Interestingly, both 7–10-week-old
Abcg1 / Ldlr / and Abcg1 /ApoE / chow-fed mice
showed dramatically reduced MB49 tumour growth compared
with chow-fed control Ldlr / and ApoE / mice, respectively
(Fig. 1h). Both genotypes also displayed a profound reduction in
tumour growth when fed a Western-like diet (Fig. 1i,j).
Collectively, these data show that Western-like diet feeding or
crossing with hypercholesterolemic mice is necessary to observe
the changes in tumour growth in young Abcg1 / mice, while
this tumour phenotype is evident in aged Abcg1 / mice fed a
chow diet.
To investigate the impact of ABCG1 deﬁciency on spontaneous
tumour metastasis, we utilized luciferase-expressing B16-F10 cells
(B16-F10-luc2). B16-F10-luc2 cells were injected subcutaneously
into Western-like diet-fed Abcg1 / or WT mice. B16-F10-luc2
tumours grew aggressively and by day 28, the difference in
tumour growth between Abcg1 / and WT mice was signiﬁcant,
but not very prominent (Supplementary Fig. 2). This aspect of
B16-F10-luc2 tumour growth allowed us to choose mice for study
that had similar-sized tumours. Lungs from mice with similar,
but average, tumour sizes in both groups were analysed for
spontaneous metastases of B16-F10 melanoma by biolumines-
cence imaging ex vivo (Supplementary Fig. 2). Subcutaneous B16
transplants have been shown to spontaneously metastasize to
lung42,43. Abcg1 / mice had signiﬁcantly diminished tumour
metastasis compared with WT mice (Supplementary Fig. 2).
Subsequently, we examined the impact of ABCG1 deﬁciency
on survival of tumour-bearing mice. MB49 tumour-bearing
Abcg1 / mice showed prolonged survival compared with WT
mice when fed a Western-like diet (Fig. 1k). Collectively, these
data demonstrate that in vivo deﬁciency of ABCG1 impairs
tumour growth and increases animal survival.
Reduction in tumours in Abcg1 / mice is immune mediated.
To determine if the impact of ABCG1 deﬁciency on tumour
growth is mediated by immune cells, we used a bone marrow
chimera approach. We measured MB49 tumour growth in
Western-like diet-fed irradiated CD45.1þ B6.SJL (WT) mice,
which were reconstituted with CD45.2þ Abcg1 / or CD45.1þ
B6.SJL bone marrow (Fig. 2a). WT mice reconstituted with
Abcg1 / bone marrow had a signiﬁcant reduction in tumour
growth over time compared with WT mice reconstituted with
WT bone marrow (Fig. 2b), demonstrating that the impact of
ABCG1 deﬁciency on tumour growth is immune cell mediated.
The tumour microenvironment contains innate and adaptive
immune cells, which display pro or antitumour functions. While
NK cells, M1 macrophages, CD4þ Th1 cells and CD8þ T have
been shown to act as tumour-ﬁghting cells, M2 macrophages and
Tregs in tumour are known to support tumour progression.
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Dendritic cells (DCs), neutrophils and NKT cells have been
shown to exert both tumour-suppressive and -promoting
effects1,44. Next we wanted to deﬁne the primary immune cell
populations in the tumour microenvironment that are affected by
the absence of ABCG1 under Western-like diet conditions. MB49
tumour cells were injected subcutaneously into either Western-
like diet-fed or chow diet-fed Abcg1 / and WT mice and
tumour-inﬁltrating immune cells were analysed by ﬂow
cytometry (For gating strategy, see Supplementary Fig. 3). We
found that the frequencies of macrophages and Tregs signiﬁcantly
decreased, whereas the frequencies of NK cells, CD4þ T cells and
CD8þ T cells signiﬁcantly increased in the tumours of Western-
like diet-fed Abcg1 / mice compared with WT mice (Fig. 2c).
No signiﬁcant differences were observed in the frequencies of
tumour-inﬁltrating neutrophils, DCs or NKT cells in chow diet-
fed or Western-like diet-fed Abcg1 / or WT mice (Fig. 2c).
These results demonstrate that ABCG1 deﬁciency changes
the balance between tumour-promoting and tumour-ﬁghting
immune cells within the tumour microenvironment.
Tumour reduction in Abcg1 / mice is myeloid cell mediated.
To determine which cell type(s) were intrinsically affected by the
absence of ABCG1 to impact tumour growth, we deleted ABCG1
selectively in either myeloid cells or T cells using Cre/loxP
technology. We generated conditional knockout mice (Abcg1ﬂ/ﬂ)
in which loxP sites ﬂank the Walker domain of exon 3 of Abcg1
and crossed them with either LysM-Cre or Lck-Cre mice for
selective deletion of ABCG1 in myeloid cells and T cells,
respectively45,46. We observed B95% deletion of ABCG1
in macrophages from Abcg1ﬂ/ﬂ-LysM-Creþ mice and 70%
deletion of ABCG1 in T cells from Abcg1ﬂ/ﬂ-Lck-Creþ mice
(Supplementary Fig. 4).
We32 and others33 have previously reported that ABCG1
deﬁciency increases proliferation of CD4þ T cells. Therefore, it is
possible that the impact of ABCG1 deﬁciency on tumour growth
might be mediated directly through T-cell intrinsic mechanisms.
To determine the impact of selective ABCG1 deletion in
T cells on tumour growth, we injected MB49 tumour cells
subcutaneously into Western-like diet-fed Abcg1ﬂ/ﬂ-Lck-Creþ
and control Abcg1ﬂ/ﬂ-Lck-Cre mice. The tumour growth in the
Abcg1ﬂ/ﬂ-Lck-Creþ mice was comparable to control (Fig. 3a),
indicating that the inhibition of tumour growth in the absence of
ABCG1 is not mediated directly through T cells. However, we
found that the tumour growth in Abcg1ﬂ/ﬂ-LysM-Creþ mice,
which have selective ABCG1 deletion in myeloid cells, was
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dramatically reduced compared with control Abcg1ﬂ/ﬂ-LysM-
Cre mice (Fig. 3b). These data indicate that the reduced tumour
growth in the absence of ABCG1 is mediated directly through
myeloid cell intrinsic mechanisms.
Subsequently, we analysed the tumour-inﬁltrating immune
cells in MB49 tumours from Western-like diet-fed Abcg1ﬂ/ﬂ-
LysM-Creþ and control mice by ﬂow cytometry. In line with the
changes in the frequencies of tumour-inﬁltrating immune cells in
Western-like diet-fed Abcg1 / mice (Fig. 2c), the frequencies
of tumour-inﬁltrating macrophages and Tregs in Abcg1ﬂ/ﬂ-LysM-
Creþ mice were signiﬁcantly lower, whereas the frequencies of
NK cells and CD4þ T cells were signiﬁcantly higher compared
with control (Fig. 3c). The frequencies of neutrophils, DCs,
CD8þ cells and NKT cells in Abcg1ﬂ/ﬂ-LysM-Creþ mice and
control mice were comparable (Fig. 3c). We also analysed
activation markers on tumour-inﬁltrating immune cells. We
observed that the mean ﬂuorescence intensity (MFI) of CD69
expression on NK cells was signiﬁcantly higher in Abcg1ﬂ/ﬂ-
LysM-Creþ mice compared with control (Fig. 3d). The MFI of
CD69 expression on CD4þ T cells, CD8þ T cells and NKT cells,
the MFI of CD86 expression on macrophages and DCs and the
MFI of CD11b expression on neutrophils were similar between
both genotypes (Fig. 3d). LysM-Cre mice have been shown to
display Cre-mediated deletion of loxP-ﬂanked target genes in
myeloid cells; mainly in macrophages and neutrophils and
partially in DCs46. In both Western-like diet-fed Abcg1 /
mice and Abcg1ﬂ/ﬂ-LysM-Creþ mice, the frequency of
macrophages was decreased, whereas no signiﬁcant differences
were observed in the frequencies or the activation of tumour-
inﬁltrating neutrophils and DCs (Figs 2c and 3c,d). Therefore,
our data suggest that ABCG1 deﬁciency in macrophages likely
promotes multiple antitumour immune responses.
Impact of ABCG1 on apoptosis of tumour macrophages. Next
we investigated why ABCG1 deﬁciency caused a reduction in the
frequency of macrophages in tumours. We ﬁrst measured the
frequency of monocytes in blood and in tumours from Abcg1ﬂ/ﬂ-
LysM-Creþ and Abcg1ﬂ/ﬂ-LysM-Cre mice fed a Western-like
diet. The frequencies of monocytes in blood and tumours were
similar in both groups (Fig. 4a), so changes in monocyte levels
was not the cause. To determine if the reduction in the frequency
of macrophages is due to an increase in macrophage cell death,
we measured apoptosis of Abcg1 / and WT macrophages in
the tumour by Annexin V staining and ﬂow cytometry. We found
that the percentage of apoptotic (Annexin Vþ live) macrophages
in Western-like diet-fed Abcg1 / mice was signiﬁcantly higher
compared with WT mice (Fig. 4b,c). The percentage of apoptotic
macrophages in chow diet-fed Abcg1 / and WT mice was
comparable (Fig. 4d,e). These data show that macrophages in the
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Figure 4 | Abcg1 / macrophages in the tumour display enhanced apoptosis under Western-like diet conditions. (a) Blood and tumour cells
from Western-like diet-fed Abcg1ﬂ/ﬂ-LysM-Creþ (n¼6) and Abcg1ﬂ/ﬂ-LysM-Cre (n¼ 6) mice were analysed by ﬂow cytometry 18 days after MB49
tumour injection. Dot plots show frequencies of monocytes (CD45þ , NK1.1 , Ly6G , CD11bþ , CD115þ ; % of live cells) in blood (top) and tumour
(bottom). (b–e) Tumour cells from Abcg1 / (n¼ 5) and WT (n¼ 5) mice were analysed for apoptosis by Annexin V staining and ﬂow cytometry 12 days
after injection of MB49 cells. (b,d) Representative pseudocolour plots show percentages of all tumour cells gated on live cells (left) and CD45þ , NK1.1 ,
Ly6G , CD11bþ , F4/80high macrophages, which are Annexin Vþ (right). Dot plots show the percentages of apoptotic (Annexin Vþ live) macrophages in
tumours from (c) Western-like-diet-fed and (e) chow diet-fed mice. Data are representative of two independent experiments with similar results
(mean±s.e.m., **Po0.01, two-tailed Student’s t-test).
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tumour of Abcg1 / mice fed a Western-like diet display
increased apoptosis.
Abcg1 / macrophages shift towards an M1 phenotype.
Excess cholesterol is exported out of the cell by the cholesterol
transporters ABCG1 and ABCA1 (refs 47,48). ABCG1 efﬂuxes
cholesterol to HDL particles23, while ABCA1 promotes
cholesterol efﬂux to lipid-poor apolipoprotein AI (apoAI)49. We
found that Abcg1 / macrophages expressed higher levels of
Abca1 compared with WT macrophages in the tumour
(Supplementary Fig. 5). Subsequently, we investigated the
phenotype of Abcg1 / macrophages in the tumour. We
analysed the expression of CD11c, which is an M1-associated
marker in tumour macrophages50. We found that in Western-like
diet-fed Abcg1 / mice, the percentage of F4/80highCD11chigh
(M1-like) macrophages was approximately ﬁve times higher than
F4/80highCD11cdim (M2-like) macrophages, whereas in WT mice
the percentages of both groups were similar (Fig. 5a,b). Moreover,
we found that in the chow diet-fed Abcg1 / mice, the
percentage of F4/80highCD11chigh (M1-like) macrophages was
only slightly (23%) higher than F4/80highCD11cdim (M2-like)
macrophages, whereas in WT mice the percentages of both
groups were similar (Supplementary Fig. 6). This shows that
although Abcg1 / macrophages display a slight shift towards
an M1 phenotype (based on CD11chigh) even under chow diet
conditions, this phenotypic shift becomes much more prominent
when the mice were fed with Western-like diet. To further analyse
the polarization phenotype of tumour macrophages in Abcg1 /
mice, we evaluated using quantitative real-time PCR the
expression of M1 markers Tnfa and Nos2 and M2 markers
Arg1, Ccl22 and Mrc1 in macrophages sorted via ﬂow cytometry
from tumours from Western-like diet-fed Abcg1 / and WT
mice. We found that the expression of Tnfa and Nos2 was
signiﬁcantly higher in tumour macrophages from Abcg1 /
mice (Fig. 5c), whereas the expression of Arg1, Ccl22 and Mrc1
was signiﬁcantly lower in Abcg1 / macrophages compared
with WT macrophages (Fig. 5d). These data point to a shift in the
phenotype of macrophages in the tumours of Abcg1 / mice
from tumour-promoting M2 macrophages to tumour-ﬁghting
M1 macrophages under Western-like diet conditions.
We also analysed macrophages in the spleens and lungs of
Western-like diet-fed MB49 tumour-bearing Abcg1 / and WT
mice by ﬂow cytometry at day 20. We found that Abcg1 /
alveolar macrophages displayed enhanced MHC II expression
compared with control, suggesting an M1 skewing. This result
is consistent with the previous studies, which reported that
Abcg1 / macrophages exhibited elevated proinﬂammatory
activity in lung28,29. Although the level of MHC II expression
in Abcg1 / spleen macrophages tended to be higher com-
pared with control, it did not reach statistical signiﬁcance
(Supplementary Fig. 7).
Next we investigated why ABCG1-deﬁcient macrophages
shift towards an M1 phenotype in the tumour. Since we showed
that Abcg1 / macrophages from Western-like diet-fed mice
displayed increased apoptosis compared with WT macrophages
(Fig. 4b,c), one possible explanation of this M1 shift could be that
Abcg1 / M2 macrophages are more prone to apoptosis than
Abcg1 / M1 macrophages. To test this, we measured apoptosis
of both M1 and M2 macrophages in tumours from Western-like
diet-fed Abcg1ﬂ/ﬂ-LysM-Creþ and Abcg1ﬂ/ﬂ-LysM-Cre mice by
Annexin V staining and ﬂow cytometry. We found that M1 and
M2 tumour macrophages from Abcg1ﬂ/ﬂ-LysM-Creþ mice
displayed similarly enhanced levels of apoptosis compared with
control mice (Fig. 5e). Similar results for apoptosis were obtained
also with staining for active Caspase-3 (Supplementary Fig. 8).
These data indicate that the shift towards M1 phenotype in the
tumour on ABCG1 deﬁciency is not the result of M2
macrophages being more prone to apoptosis.
Next we examined if Abcg1 / macrophages are intrinsically
biased towards M1 polarization. To test this, we generated bone
marrow-derived macrophages (BMDMs) from Abcg1 / and
WT mice and polarized them to either an M1 phenotype by
interferon-gamma (IFNg)/LPS stimulation or to an M2 pheno-
type by interleukin-4 (IL-4) stimulation in vitro. First, we
measured Abcg1 and Abca1 mRNA expression in polarized WT
BMDMs. Both IFNg/LPS and IL-4 stimulation signiﬁcantly
increased Abcg1 expression, but decreased Abca1 expression in
WT macrophages (Supplementary Fig. 9). Next we determined
the expression of M1 and M2 markers in polarized Abcg1 /
and WT BMDMs. We found that Abcg1 / macrophages had
increased production of the M1 markers tumour-necrosis
factor-a (TNFa; 50%) and nitric oxide (NO; 50%) after IFNg/
LPS stimulation compared with control (Fig. 5f). Moreover,
Abcg1 / macrophages displayed enhanced expression of the
M1 activation marker proteins MHC II (2.1-fold) and CD86
(B50%) when stimulated with the M1 inducers IFNg/LPS
(Fig. 5f). In contrast, Abcg1 / macrophages displayed
decreased expression of the M2 markers Arg1 (twofold), Mrc1
(40%) and Retnla (Fizz1; 2.3-fold) after stimulation with the M2
inducer IL-4 (Fig. 6g). Arg1 (B20-fold) and Mrc1 (approximately
twofold) expression levels were also signiﬁcantly lower in non-
polarized (unstimulated) Abcg1 / macrophages (Fig. 5g).
These data indicate that Abcg1 / macrophages exhibit an
intrinsic bias towards M1 polarization. Altogether these data
show that the M1 shift of the Abcg1 / macrophages in the
tumour is not due to increased apoptosis of M2 macrophages,
but rather that Abcg1 / macrophages are biased toward M1
polarization.
Abcg1 / macrophages accumulate cholesterol and choles-
terol derivatives, such as 7-ketocholesterol (7-KC)22,51. To
investigate if cholesterol and cholesterol derivatives have any
impact on the M1 phenotype in macrophages, we incubated
WT BMDMs with cholesterol and other sterols, including 7a-
hydroxycholesterol (7a-OHC), 25-hydroxycholesterol (25-OHC),
27-hydroxycholesterol (27-OHC), desmosterol and 7-KC. After
that, we either polarized BMDMs to an M1 phenotype by IFNg/
LPS stimulation or left them unstimulated. We found that
incubation with cholesterol or 7-KC increased the levels of M1
markers, MHC II and TNFa in unstimulated macrophages.
Incubation with cholesterol, but not 7-KC, also increased the
levels of MHC II and TNFa after IFNg/LPS stimulation
(Fig. 6a,b). Incubation with 7a-OHC, 25-OHC, 27-OHC or
desmosterol did not signiﬁcantly alter the expression of M1
markers in either unstimulated or IFNg/LPS- stimulated
macrophages (data not shown). Thus, WT macrophages display
an increase in the levels of M1 markers when incubated with
cholesterol or 7-KC, suggesting that the M1-bias in Abcg1 /
macrophages is likely due to the accumulation of these sterols.
To better understand why Abcg1 / macrophages exhibit
an intrinsic bias towards M1 polarization, we examined
the activation of the transcription factor NF-kB, which is
well established as playing a critical role in the induction
of proinﬂammatory gene expression in macrophages52.
Phosphorylation of p65 subunit of NF-kB helps stabilize NF-kB
in the nucleus for gene transcription53 and thereby is widely used
as an indicator of NF-kB activation. We evaluated the levels of
NF-kB p65 (Ser 529) phosphorylation in unstimulated Abcg1 /
and WT BMDMs by ﬂow cytometry. Abcg1 / macrophages
showed anB50% higher level of p65 phosphorylation compared
with WT macrophages (Fig. 6c,d), indicating that the absence of
ABCG1 results in an increased NF-kB activation in macrophages,
which is a likely cause for the observed M1 phenotype bias.
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Figure 5 | Abcg1 / macrophages shift towards an M1 phenotype in the tumour. (a,b) Tumour cells from Western-like diet-fed Abcg1 / (n¼ 6)
and WTmice (n¼6) mice were analysed by ﬂow cytometry 20 days after injection of MB49 cells. (a) Representative contour plots and bar graphs
show percentages of CD11chigh (M1-like) and CD11cdim (M2-like) macrophages (CD45þ , NK1.1 , Ly6G , CD11bþ , F4/80high) in the tumour.
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tailed Student’s t-test). Unstim., unstimulated.
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Abcg1 / macrophages show enhanced tumour cytotoxicity.
Next we investigated how the shift of macrophages towards an
M1 phenotype in the absence of ABCG1 reduces tumour growth.
M2-like TAMs support tumour growth through various
mechanisms including promoting angiogenesis6–9 Therefore,
ABCG1 deﬁciency might decrease the ability of macrophages to
promote tumour angiogenesis. To test this, we assessed the
expression levels of endothelial cell markers in tumours from
Abcg1ﬂ/ﬂ-LysM-Creþ and Abcg1ﬂ/ﬂ-LysM-Cre mice by ﬂow
cytometry. We found comparable levels of CD45 CD31þ
CD34þ vascular endothelial cells in tumours from both mice
groups (Fig. 7a,b), indicating that ABCG1-deﬁcient macrophages
are similar to WT macrophages in terms of promoting tumour
angiogenesis, making this an unlikely mechanism.
Unlike M2-like TAMs, M1 macrophages can be cytotoxic to
tumour cells and, in this way, can prevent tumour growth54.
To investigate if the impact of ABCG1 deﬁciency on tumour
growth can be through increased ability of macrophages to kill
tumour cells directly, we performed an in vitro cytotoxicity assay.
In brief, we polarized bone marrow-derived Abcg1 / and WT
macrophages to M1 phenotype by IFNg/LPS stimulation and co-
cultured these M1 macrophages with MB49 tumour cells. We
assessed the viability of tumour cells by ﬂow cytometry. We found
that the frequency of dead tumour cells (CD45 F4/80
7-AADþ ) was 40% higher when they were co-cultured with
Abcg1 / macrophages, compared with WT macrophages
(Fig. 7c,d). This indicates that Abcg1 / macrophages display
enhanced cytotoxicity for tumour cells, making this a likely
explanation for the reduced tumour growth observed in vivo.
Discussion
In this study, we identify a novel role for the cholesterol
transporter ABCG1 as a modulator of tumour immunity. The
absence of ABCG1 inhibits tumour growth through the
modulation of macrophage survival and phenotype within the
tumour. Collectively, our data demonstrate an important new
concept that cholesterol homeostasis in immune cells can
determine the outcome of tumour growth in vivo.
LysM-Cre mice have been shown to display Cre-mediated
deletion of loxP-ﬂanked target genes in myeloid cells, mainly in
macrophages and neutrophils and partially in DCs46. In tumours
from Western-like diet-fed Abcg1 / mice and Abcg1ﬂ/ﬂ-LysM-
Creþ mice, the frequency of macrophages was reduced, while the
frequencies and the activation of neutrophils and DCs were
similar compared with control (Figs 2c and 3c,d). Moreover, we
showed that ABCG1-deﬁcient macrophages exhibit an intrinsic
bias toward tumour-ﬁghting M1 polarization and display
enhanced ability to kill tumour cells directly (Fig. 7c,d).
Therefore, we conclude that the reduced tumour growth in the
absence of ABCG1 is mediated through macrophage-intrinsic
mechanisms.
Increased apoptosis of Abcg1 / macrophages was also
reported in atherosclerosis studies in mice, in which increased
numbers of apoptotic macrophages were found within athero-
sclerotic lesions of Western-like diet-fed Abcg1 / ApoE /
mice and Ldlr / mice transplanted with Abcg1 / bone
marrow26,27. In addition, Abcg1 / macrophages have been
shown to undergo apoptosis after a challenge with oxLDL26,51
in vitro. Increased apoptosis of ABCG1-deﬁcient macrophages is
a result of the accumulation of speciﬁc toxic oxysterols, including
7-KC, which are known to induce apoptosis27,51. 7-KC and
related oxysterols have been shown to be selectively exported out
of the cell by ABCG1, but not by ABCA1 (ref. 51). Furthermore,
the observed shift of Abcg1 / macrophages in the tumour
towards a proinﬂammatory M1 phenotype (Fig. 5a–d) is in
concordance with a previous study in atherosclerosis, which
reported that macrophages from Abcg1 / mice fed a Western-
like/high-cholesterol diet exhibited elevated proinﬂammatory
activity31. Macrophages are known to accumulate cholesterol in
the absence of ABCG1 (ref. 22). Our data demonstrate that
macrophages display an increase in the levels of M1 markers
when incubated with cholesterol or 7-KC (Fig. 6a,b), suggesting
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that the M1-bias in Abcg1 / macrophages is likely due to the
excess sterol accumulation. In addition, similar to a previous
report, which showed enhanced content of nuclear NF-kB p65 in
Abcg1 / peritoneal macrophages after LPS stimulation30, we
observed elevated NF-kB p65 phosphorylation in Abcg1 /
BMDMs (Fig. 6c,d). A previous study by Li et al.55 reported that
free cholesterol accumulation in macrophages induced the
production of proinﬂammatory cytokines through the activation
of IkB kinase/NF-kB pathway. Therefore, based on our data,
we surmise that an increased cholesterol accumulation in
macrophages in the absence of ABCG1 causes NF-kB acti-
vation, which polarizes these macrophages to a proinﬂammatory/
tumour-ﬁghting M1 phenotype. M1 macrophages produce TNFa
and NO, which can mediate cytolysis of tumour cells54. Thus, the
enhanced production of TNFa and NO in Abcg1 / M1
macrophages that we reported here (Fig. 5c,f) is likely the cause of
the observed increase in direct cytotoxicity of Abcg1 /
macrophages for tumour cells (Fig. 7c,d).
In most tumour models, the majority of the macrophages in
tumours display a tumour-promoting M2 phenotype5. Our study
shows that ABCG1 deﬁciency not only reduces the number of
macrophages within the tumour, but also causes a shift of the
remaining macrophages to a tumour-ﬁghting M1 phenotype.
Therefore, ABCG1 may constitute a therapeutic target for cancer.
TAMs can promote tumour growth by different mechanisms.
Production of CCL22 by immunosuppressive TAMs has been
shown to recruit tumour-promoting Tregs to the tumour site10.
Thus, our observation of reduced Treg frequency in the tumour
in the absence of ABCG1 could be explained by a reduction in the
frequency of TAMs (Figs 2c and 3c) and a phenotypic shift of the
remaining TAMs to M1 macrophages, which are not potent
CCL22 producers (Fig. 5c,d). Tregs suppress the expansion of
antitumour effector cells including NK cells and CD4þ T cells10.
Therefore, our observation of an increase in the frequency of NK
cells and CD4þ T cells in the absence of ABCG1 could be
explained by a decrease in the frequency of Tregs in the tumour
(Figs 2c and 3c). Our data support the notion that M1 phenotypic
shift of Abcg1 / macrophages with reduced CCL22 production
results in reduced Treg recruitment, which in turn increases
tumour inﬁltration by NK cells and CD4þ T cells. Since these
cells are well-established tumour-ﬁghting cells1, an increase in
their frequency would have an impact on tumour growth.
Collectively, our data support the concept that the absence of
ABCG1 in macrophages drives changes in macrophage-intrinsic
cytokine production and as such, could increase NK cell and
CD4þ T-cell inﬁltration into the tumour to further prevent
tumour growth.
Our study suggests that intrinsic loss of ABCG1 in macro-
phages is of critical importance for the mechanisms behind the
effects on tumour growth. Our data support the notion that
accumulation of cholesterol in macrophages in the absence of
ABCG1 impacts their survival and phenotype, thus changing
their function in the tumour. Since Abcg1 / macrophages
cannot efﬂux cholesterol properly, more cholesterol accumulates
in Abcg1 / macrophages compared with WT macrophages,
which has been well documented22. In young Abcg1 /
mice, macrophage cholesterol accumulation is accelerated by
Western-like diet feeding or by crossing the mice onto a
hypercholesterolemic mouse model background. However, our
ﬁnding that aged Abcg1 / mice display reduced tumour
growth when fed a chow diet supports the notion that
macrophages in older Abcg1 / mice accumulate more
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cholesterol over time44. Thus, in the aged Abcg1 / mice, the
tumour phenotype becomes evident even on a chow diet.
Enhanced expression of ABCG1 but reduced expression of
ABCA1 after LPS/IFNg or IL-4 stimulation in WT macrophages
(Supplementary Fig. 9) point to an importance of ABCG1 in
macrophage activation. Increased expression of ABCA1 in
Abcg1 / TAMs is not surprising (Supplementary Fig. 5), since
we32,34 and others36,56 have previously shown that genetic
deletion of one cholesterol transporter, either ABCG1 or
ABCA1, is compensated for by an upregulation of the other
transporter. Nevertheless, neither ABCG1 nor ABCA1 can fully
compensate for the loss of the other20. However, we cannot rule
out the possibility that changes in ABCA1 expression contributed
to our observed ﬁndings of reduced tumour growth in Abcg1 /
mice. Future studies using ABCA1-deﬁcient mice will be
useful to delineate the roles of these two transporters in tumour
immunity.
From many perspectives, atherosclerosis and cancer are
fundamentally different. However, the immune system plays a
major role in the progression of both diseases. Human population
and animal studies clearly demonstrate that HDL protects against
atherosclerosis57. Interestingly, meta-analysis of lipid-altering
therapies has indicated an inverse relationship between plasma
HDL levels and incidence of cancer58. In concordance with this
report, a recent study has shown that apoAI, the major protein
component of HDL, suppresses tumour growth and metastasis in
mice via the modulation of immune responses59. Collectively,
these studies suggest that HDL has a role both in atherosclerosis
and cancer. ABCG1 deﬁciency in immune cells has been shown
to protect mice from atherosclerosis development26,36. By
demonstrating that myeloid cell-speciﬁc ABCG1 deletion
suppresses tumour growth, our present study suggests that
ABCG1 might link immunity in atherosclerosis and cancer.
In sum, our study identiﬁes ABCG1 as a novel mediator of
antitumour immune responses. It deﬁnes an important role for
cholesterol transporters in tumour immunity and provides a link
between lipid homeostasis and cancer. Understanding how
ABCG1 and cholesterol metabolism in immune cells impacts
antitumour immune responses could lead to development of
entirely new therapeutic approaches for cancer immunotherapy.
Methods
Mice. C57BL/6J mice (000664), Ldlr / mice (002207) and ApoE / mice
(002052) were purchased from The Jackson Laboratory (Bar Harbor, ME).
Abcg1 / /lacZ knock-in mice were purchased from Deltagen (San Mateo, CA)
and are congenic to a C57BL/6J background (backcrossed 14 generations).
B6.SJL-Ptprca/BoyAiTac mice (CD45.1 congenic, 004007) were purchased from
Taconic Farms (Germantown, NY). Abcg1 / mice were crossed with Ldlr /
and ApoE / mice to obtain Abcg1 / Ldlr / and Abcg1 /ApoE /
mice, respectively. Conditional knockout Abcg1ﬂ/ﬂ mice (C57BL/6J background) in
which loxP sites ﬂank the Walker domain of exon 3 of Abcg1 were generated for
our laboratory using InGenious Targeting Laboratory (New York). An B10.3-kb
region used to construct the targeting vector was ﬁrst subcloned from a positively
identiﬁed BAC clone using homologous recombination. The region was designed
such that the short homology arm extends 2.2 kb 50 to lox P/FRT-ﬂanked Neo
cassette. The long homology arm ends on the 30 side of lox P/FRT-ﬂanked Neo
cassette and is B8.1-kb long. The single lox P site is inserted upstream of exon 3,
and the lox P/FRT-ﬂanked Neo cassette is inserted downstream of exon 3. The
target region is 1.5 kb including exon 3. The targeting vector is conﬁrmed by
restriction analysis after each modiﬁcation step and by sequencing using primers
designed to read from the selection cassette into the 30 end of the long homology
arm (N7) and the 50 end of the short homology arm (N1), or from primers that
anneal to the vector sequence, P6 and T7, and read into the 50 and 30 ends of the
BAC sub clone. Abcg1ﬂ/ﬂ mice were crossed with Lck-Cre mice (003802, The
Jackson Laboratory) to obtain Abcg1ﬂ/ﬂ-Lck-Creþ and control Abcg1ﬂ/ﬂ-Lck-Cre
mice, and crossed with LysM-Cre mice (004781, The Jackson Laboratory) to obtain
Abcg1ﬂ/ﬂ-LysM-Creþ and Abcg1ﬂ/ﬂ-LysM-Cre mice. All the mice used in this
study were female and 7–10 weeks old, except for the tumour growth experiment in
the aged Abcg1 / and C57BL/6 (WT) mice, which were 6–7 months old. Mice
were fed a standard rodent chow diet containing 0% cholesterol and 5% calories
from fat (Pico lab, #5053) or Western-like diet containing 0.2% cholesterol and
42% calories from fat (Harlan Laboratories, #TD88137). The mice were housed in
microisolator cages in a pathogen-free animal facility of the La Jolla Institute for
Allergy and Immunology.
The plasma lipid proﬁle analyses were performed at day 12, because this is the
very earliest time that signiﬁcant differences were observed in tumour growth. Day
12 is also the time when differences in macrophage apoptosis were observed, which
then later on leads to a more prominent difference in tumour growth. Tumour
growth was measured until days 18–20 and that is the time when the frequency and
phenotype of the immune cells within the tumour were analysed.
All the experiments followed the guidelines of the La Jolla Institute for Allergy
and Immunology Animal Care and Use Committee and approval for use of rodents
was obtained from the La Jolla Institute for Allergy and Immunology according to
criteria outlined in the Guide for the Care and Use of Laboratory Animals from the
National Institutes of Health. Mice were euthanized by CO2 inhalation.
Cell lines and reagents. MB49-bladder carcinoma and B16-F1 melanoma cells
were derived from C57BL/6 mice and obtained from American Type Culture
Collection. The B16-F10-luc2 cell line was established by Caliper Life Sciences
by transduction of lentivirus containing luciferase 2 gene under the control of
human ubiquitin C promoter. Tumour cells were cultured in R5 medium con-
taining RPMI 1640, 5% heat-inactivated fetal bovine serum, 50Uml 1 penicillin
and 50mgml 1 streptomycin. Cells were injected into mice after reaching 60–80%
conﬂuency.
Flow cytometry antibodies including anti-mouse APC-F4/80 (BM8; 1/100),
FITC-Ly6G (RB6-8C5; 1/200), APC/Cy7 or AF700-CD45 (30-F11; 1/200),
AF700-CD45.2 (104; 1/200), PerCP/Cy5.5-NK1.1 (PK136; 1/100), e-Fluor 450-
CD4 (RM4-5; 1/200), FITC-TCRb (H57-597; 1/400), PE-CD25 (PC61.5; 1/100),
APC-Foxp3 (FJK-16s; 1/100), AF700-CD34 (RAM34; 1/200) and e-Fluor 450-
MHC II (M5/114.15.2; 1/200), were purchased from eBioscience (San Diego, CA);
PE-Cy7-CD11b (M1/70; 1/800), PE-CD11c (HL3; 1/300), FITC-CD45.1 (A20;
1/200), APC/Cy7-CD8a (53-6.7; 1/200), PE-Cy7-CD69 (H1.2F3; 1/400), PE-CD31
(MEC 13.3; 1/300) and PE-phospho-p65 (S529; K10-895.12.50; 1/10), were
purchased from BD Biosciences (San Jose, California); PerCP/Cy5.5-CD19 (6D5;
1/100), PE-CD115 (AFS98; 1/100) and AF700-CD86 (GL-1; 1/200) were purchased
from Biolegend (San Diego, CA). CD16/CD32 (2.4G2; 1/200) antibody was
purchased from BD Biosciences. Ultrapure LPS (Escherichia coli 0111:B4) was
purchased from InvivoGen (San Diego, CA), murine rIFNg and rIL-4 were
purchased from R&D Systems (Minneapolis, MN), murine macrophage colony-
stimulating factor (M-CSF) was purchased from PeproTech (Rocky Hill, NJ) and
RPMI 1640 medium was purchased from Invitrogen (Carlsbad, CA). Fetal bovine
serum, Collagenase IV, water-soluble cholesterol, 7a-OHC, 25-OHC, 27-OHC,
desmosterol and 7-KC were purchased from Sigma-Aldrich (St Louis, MO). DNase
I was purchased from Roche (Basel, Switzerland), PBS was purchased from Thermo
Scientiﬁc (Rockford, IL) and Ficoll-Paque plus was purchased from GE Healthcare
(Pittsburgh, PA).
Measurement of tumour growth/metastasis and survival. MB49 or B16-F1
cells (105) in 100ml PBS were injected subcutaneously into the right ﬂanks of
female age-matched 7–10-week-old Abcg1 / , C57BL/6 (WT), Abcg1 /
Ldlr / , Ldlr / , Abcg1 /ApoE / , ApoE / , Abcg1ﬂ/ﬂ-Lck-Creþ ,
Abcg1ﬂ/ﬂ-Lck-Cre , Abcg1ﬂ/ﬂ-LysM-Creþ and Abcg1ﬂ/ﬂ-LysM-Cre mice or
6–7-month-old Abcg1 / and WT mice. Mice were fed with either Western-like
diet or chow diet beginning a week before injection of tumour cells. Tumour
diameters were measured using a digital caliper and tumour volume was calculated
using the formula V¼D d2/2, where V is the tumour volume, D is the largest
measured tumour diameter and d is the smallest measured tumour diameter. For
the survival experiments, the mice with tumour volume reaching 2,000mm3 were
considered as dead and euthanized. To measure spontaneous lung metastasis, 105
luciferase-expressing B16-F10 cells (B16-F10-luc2) in 100ml PBS were injected into
female age-matched Abcg1 / and C57BL/6 mice subcutaneously. Mice were fed
with Western-like diet beginning a week before injection of tumour cells. B16-F10-
luc2 tumours grow more aggressively than B16-F1 tumours, which allowed us to
choose mice for study that had similar-sized tumours. At 28 days after B16-F10-
luc2 tumour inoculation, mice with similar, but average, tumour sizes in both
groups were anaesthetized by inhalation of isoﬂurane (Butler Animal Health
Supply) and 1mg D-Luciferin (Caliper Life Sciences, Waltham, MA) in 100 ml PBS
was delivered into each mouse retro-orbitally. Mice were euthanized 2min after D-
Luciferin injection, lungs were harvested and lung metastases were measured using
an IVIS 200 Bioluminescence Imager (Caliper Life Sciences, Hopkinton, MA).
Measurement of plasma lipoproteins. Mice were fed with either chow diet or
Western-like diet beginning a week before injection of tumour cells. Blood
(in EDTA) was collected from chow diet-fed or Western-like diet-fed mice 12 days
after MB49 tumour inoculation. Plasma lipoprotein proﬁles were obtained by fast
protein liquid chromatography as described previously60,61. In brief, equal volumes
of plasma from ﬁve mice per group were pooled and 200ml of this pooled plasma
was applied to a set of 2 Superose 6 (HR 10/30) columns linked in series.
Lipoproteins were eluted by size exclusion into 0.5-ml fractions in EDTA/NaCl/
NaN3 (1mmol l 1; 0.154mol l 1; 0.02%) at a ﬂow rate of 0.5mlmin 1.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7354 ARTICLE
NATURE COMMUNICATIONS | 6:6354 | DOI: 10.1038/ncomms7354 | www.nature.com/naturecommunications 11
& 2015 Macmillan Publishers Limited. All rights reserved.
Cholesterol was measured in each fraction using an enzymatic cholesterol kit
(Wako) according to the manufacturers’ instructions.
Generation of bone marrow chimeras. Recipient B6.SJL mice were irradiated in
two doses of 500 rad each (for a total of 1,000 rad) 4 h apart. Bone marrow cells
from both femurs and tibias of B6.SJL (CD45.1) and Abcg1 / (CD45.2) donor
mice were collected under sterile conditions. Bones were centrifuged for the col-
lection of marrow and the cells were washed and resuspended in PBS for injection.
Bone marrow cells (107) from B6.SJL or Abcg1 / mice in 200ml PBS were
delivered retro-orbitally into each recipient mouse. Recipient mice were housed in
a barrier facility under pathogen-free conditions and were provided autoclaved
acidiﬁed water with antibiotics (trimethoprim-sulfamethoxazole) and were fed
autoclaved food. The chimeric mice were fed with Western-like diet starting
6 weeks after bone marrow reconstitution.
Flow cytometry. Tumours were meshed through a 100-mm strainer (Fisher
Scientiﬁc, Pittsburg, PA) and then ﬁltered through a 40-mm strainer. Single-cell
suspension was resuspended in 100 ml ﬂow cytometry staining buffer (1% bovine
serum albumin plus 0.1% sodium azide in PBS). Fcg receptors were blocked with
CD16/32-blocking antibody for 10min and surface antigens on cells were stained
for 30min at 4 C. LIVE/DEAD Fixable Dead Cell Stain (Invitrogen) was used for
analysis of viability, and forward- and side-scatter parameters were used for
exclusion of doublets from analysis. Antibody clones and dilutions used are listed
above. For intracellular staining, cells were ﬁxed and permeabilized with the
Cytoﬁx/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences; for
cytoplamis proteins) or Foxp3 Staining Buffer Set (eBioscience; for nuclear pro-
teins) after the cell surface staining. Cells were stained with directly conjugated
ﬂuorescent of Foxp3 antibody for 30min at 4 C and with directly conjugated
ﬂuorescent of NF-kB phospho-p65 (Ser 529) antibody for 30min at RT. Apoptosis
of macrophages in tumour was measured by ﬂow cytometry using a PE Annexin
V Apoptosis Detection Kit 1 or a FITC active Caspase-3 Apoptosis Kit (BD
Biosciences) according to the manufacturer’s instructions.
Cell ﬂuorescence was assessed using LSR-II (BD Biosciences) and data were
analysed with FlowJo software (TreeStar, Ashland, OR). Macrophages (CD45þ ,
NK1.1 , Ly6G , CD11bþ , F4/80high), neutrophils (CD45þ , NK1.1 , Ly6Gþ ,
CD11bþ ), myeloid DCs (CD45þ , NK1.1 , Ly6G , F4/80 , CD11bþ
CD11cþ ), monocytes (CD45þ , NK1.1 , Ly6G , CD11bþ , CD115þ ), NK cells
(CD45þ , TCRb , NK1.1þ ), CD4þ T cells (CD45þ , TCRbþ , NK1.1 , CD4þ ),
CD8þ T cells (CD45þ , TCRbþ , NK1.1 , CD8þ ), NKT cells (CD45þ , TCRbþ ,
NK1.1þ ) and Tregs (CD45þ , TCRbþ , NK1.1 , CD4þ ,CD25þ , Foxp3þ ) were
identiﬁed with the appropriate gating.
Cell sorting. Tumours from WT and Abcg1 / mice at day 20 were enriched for
CD11bþ cells by positive selection with mouse CD11bþ positive selection kit
(Stem Cell Technologies, Vancouver, Canada) according to the manufacturer’s
instructions, before cell sorting. Surface antigens on enriched CD11bþ cells were
then stained as described above, followed by macrophage (Ly6G , NK1.1 ,
CD11bþ , F4/80high) sorting with a FACSAria cytometer (BD Biosciences).
Peritoneal lavage from Abcg1ﬂ/ﬂ-LysM-Creþ and Abcg1ﬂ/ﬂ-LysM-Cre mice
5 days post thioglycollate injection was sorted for macrophages (F4/80high) and
splenocytes from Abcg1ﬂ/ﬂ-Lck-Creþ and Abcg1ﬂ/ﬂ-Lck-Cre mice were sorted
for T cells (CD3þ ) using FACSAria cytometer.
Tumour angiogenesis. Tumours were minced and digested with Collagenase IV
(400Uml 1) in the presence of DNase I (20 mgml 1) in RPMI medium at 37 C
for 30min. Cell suspension was ﬁltered through a 40-mm strainer and resuspended
in warm R5 medium and incubated at 37 C for 30min. The cells were stained with
ﬂuorophore-conjugated antibodies against CD45, CD31, CD34 and analysed by
ﬂow cytometry.
Generation and M1/M2 polarization of BMDMs. BMDMs were prepared as
described previously62,63. In brief, bone marrow cells were cultured in standard
tissue culture plates in the presence of 10 ngml 1 M-CSF overnight. Non-
adherent cells from this initial culture were then transferred to low-attachment six-
well plates (Corning Life Sciences, Tewksbury MA) in 4ml R5 medium containing
30% L929 conditioned medium and 10 ngml 1 M-CSF per well for 7 days, adding
more medium on days 3 and 6. After that, the cells were puriﬁed by centrifugation
over Ficoll-Paque plus. Cells were veriﬁed to be 98% CD11bþ , F4/80þ , MHC
IIlow, CD80low, CD86low by ﬂow cytometry.
WT and Abcg1 / BMDMs were allowed to rest at 37 C over night before
stimulation. For M1 polarization, macrophages were either stimulated with IFNg
(20 ngml 1) for 12 h followed by LPS (100 ngml 1) stimulation for 4 h (for MHC
II and CD86 analysis) or stimulated with IFNg (20 ngml 1)þ LPS (100 ngml 1)
overnight (for TNFa and NO analysis). For M2 polarization, macrophages were
stimulated with IL-4 (20 ngml 1) for 16 h.
Stimulation of macrophages with cholesterol and -derivatives. WT BMDMs
were allowed to rest at 37 C over night before stimulation. The next day,
macrophages were preincubated with water-soluble cholesterol (20 mgml 1),
7a-OHC (1mM), 25-OHC (1mM), 27-OHC (1mM), desmosterol (5 mM) or 7-KC
(5 mM) for 2 h. Next, macrophages were either left unstimulated or stimulated with
IFNg (20 ngml 1) for 12 h followed by LPS (100 ngml 1) stimulation for 4 h
(for MHC II analysis) or stimulated with IFNg (20 ngml 1)þ LPS (100 ngml 1)
overnight (for TNFa analysis).
Cytokine and NO measurements. The supernatants were collected and TNFa
was measured by ELISA (eBioscience) and NO (as nitrite) was measured by the
Griess Reagent System (Promega, Madison, WI) according to the manufacturers’
instructions.
In vitro tumour cytotoxicity assay. WT and Abcg1 / BMDMs were plated in
round well 96-well plates as 4 105 cells per well in 200 ml R5 and stimulated with
IFNg (20 ngml 1) and LPS (100 ngml 1) for 24 h. The cells were washed with
R5 twice and co-cultured with 104 MB49 tumour cells (40:1 ratio of effector
(macrophages): target cells (tumour cells) ). Twenty four hours later, the cells
were washed with PBS and treated with Accutase cell detachment solution (BD
Biosciences). Tumour cell viability was determined with 7-aminoactinomycin D
(7-AAD) staining by ﬂow cytometry. Tumour cytotoxicity was calculated as % of
7-AADþ tumour cells (CD45 , F4/80 ) co-cultured with macrophages (CD45þ ,
F4/80þ )—% 7-AADþ of tumour cells alone.
Quantitative real-time PCR. Total cellular RNA of macrophages was collected
with an RNeasy Plus Micro Kit according to the manufacturer’s protocol (Qiagen,
Valencia, CA). RNA purity and quantity was measured with a nanodrop spec-
trophotometer (Thermo Scientiﬁc). Approximately 500 ng RNA was used for
synthesis of cDNA with an Iscript cDNA Synthesis Kit (Bio-Rad, Hercules, CA).
Total cDNA was diluted 1:20 in H2O and a volume of 9 ml was used for each
real-time condition with a MyIQ Single-Color Real-Time PCR Detection
System (Bio-Rad) and TaqMan Gene Expression Mastermix and Arg1
(# Mm00475988_m1), Ccl22 (# Mm00436439_m1), Mrc1 (# Mm00485148_m1),
Tnfa (# Mm00443258_m1), Rtnla (# Mm00445109_m1), Nos2 (# Mm00440502_
m1), Abcg1 (# Mm01348250_m1) and Abca1 (# Mm01350760_m1) TaqMan
primers (Applied Biosystems). Data were analysed and presented on the basis of
the relative expression method64. The formula for this calculation is as follows:
relative expression¼ 2 (SD Ct–CDC t) where DCt is the difference in the threshold
cycle between the gene of interest and the housekeeping gene (18S), S is the
Abcg1 / mouse and C is the WT mouse.
Statistical analyses. Data for all experiments were analysed with Prism software
(GraphPad). Two-way analysis of variance test, long-rank test, unpaired Student’s
t-test and Wilcoxon-matched-pairs signed rank test were used for comparison of
experimental groups when appropriate. The data shown are the means±s.e.m.
P values of less than 0.05 were considered statistically signiﬁcant.
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